Here, for the first time, we report a central role of SRC in mediating intrinsic and adaptive “bypass”-resistance to MEK inhibition (MEKi), primarily in cancer stem cells (CSCs), which may help development of a biomarker-driven drug combination (MEKi + SRCi) to treat problematic subpopulations of CRC. This evidence concerns the gene SRC and colorectal carcinoma.